Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024Clinical and Translational ScienceOpen Access

Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

FTF. TettamantiHKHolly KimkoSSShringi Sharma

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tettamanti et al. (2024) studied this question.

synapsesocial.com/papers/68e5dfd6b6db64358757448fhttps://doi.org/10.1111/cts.13905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival2025
  2. 2Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.2026 · 3 citations
  3. 3Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  4. 4From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of <scp>MRD</scp> in <scp>CLL</scp> Management2026 · 3 citations
  5. 5Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial2026